Pharming announces positive results of Phase II/III for the treatment of activated PI3K delta syndrome

Leiden, The Netherlands,Business News: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/NASDAQ: PHAR) announces positive results from the pivotal Phase II/III blinded randomized, placebo-controlled registration-enabling

Read More

Share